Publisher
Medical Device Regulatory News and Industry Insights
In a major push to strengthen India’s medical device ecosystem, the Centre has announced the creation of 1,500 new posts within the Central Drugs Standard Control Organisation (CDSCO). Speaking at the 9th edition of India Medical Device 2026, Drugs Controller General of India (DCGI) Dr. Rajeev Raghuvanshi highlighted that this massive workforce expansion, combined with game-changing regulatory reforms, will build specialized scientific capacity, accelerate device evaluations, and simplify R&D processes across the country.
Related Reads: Government Launches Incentive Scheme for Medical Device Manufacturers
1. Building a Specialized Regulatory Workforce: 1,500 New CDSCO Posts
A substantial portion of the 1,500 newly sanctioned positions will be dedicated to creating an internal scientific cadre within the medical device regulatory framework. This initiative aims to address manpower constraints, provide technical guidance to innovators, and enhance application evaluation.
Key elements of this workforce expansion include:
Internal Scientific Cadre: The new positions will bring on board specialists from engineering backgrounds, software developers, AI experts, and ophthalmic medical device regulators.
Dedicated Medical Devices Vertical: CDSCO has established an independent medical devices vertical with separate leadership to streamline device-specific regulatory functions. Around 30–35 new positions are already under recruitment via the Union Public Service Commission (UPSC).
Revised Leadership Eligibility: In a landmark decision, recruitment rules for the post of DCGI have been updated. Professionals with engineering qualifications and hands-on medical device industry experience are now eligible for consideration for India’s top drug regulator position.
This expanded internal capacity aims to reduce dependence on external review committees and improve approval predictability for manufacturers and startups alike.
2. Key Regulatory Reforms Transforming India’s MedTech Landscape
Alongside the workforce expansion, the DCGI detailed several regulatory reforms designed to reduce compliance friction, foster innovation, and align India with international regulatory benchmarks:
EU Recognition for Clinical Waivers: The European Union (EU) has officially been added to India’s list of recognized trusted regulatory jurisdictions alongside the US, UK, Canada, Australia, and Japan. Medical devices already approved in the EU are now eligible for streamlined clinical investigation waivers in India.
Proposed T-Licence Waiver for R&D: The Drugs Technical Advisory Board (DTAB) has approved a proposal to waive the T-Licence (Test Licence) requirement for medical device research and development. Once notified, manufacturers will be free to conduct early-stage R&D and testing without seeking prior regulatory permits.
Medical Device Software Framework: The recent release of formal guidelines for Medical Device Software (MDSW / SaMD) provides a structured regulatory pathway for software-based and AI-driven medical technologies.
These structural shifts signal a transition toward a more agile, scientifically grounded, and business-friendly regulatory framework in India.
Related Read: Government Releases Medical Device Scheme Data
How Operon Strategist Can Help
As CDSCO expands its scientific cadre and implements major regulatory reforms—such as T-licence waivers and EU recognition—medical device manufacturers must adapt their technical documentation and submission strategies to meet evolving expectations. Operon Strategist offers comprehensive regulatory consulting to help organizations navigate these changes and achieve seamless market access.
Our key services include:
CDSCO Medical Device Registration: End-to-end support for manufacturing licenses, import approvals, device classifications, and regulatory submissions under CDSCO guidelines.
Medical Device Software (SaMD / MDSW) Regulatory Consulting: Technical documentation, IEC 62304 compliance, cybersecurity framework setup, and risk classification (ISO 14971) aligned with CDSCO’s software guidelines.
Global Regulatory Alignment & CE Marking: Leveraging CE Marking (EU MDR/IVDR) or US FDA clearances to secure accelerated CDSCO clinical investigation waivers under the expanded trusted jurisdiction framework.
Quality Management System (ISO 13485) & DHF Development: Building robust Quality Management Systems and Design History Files (DHF) to ensure R&D projects transition smoothly into commercial manufacturing post-T-licence waiver.
Plant Layout Detail Engineering & Process Optimization: Assisting manufacturers expanding under national incentive schemes with audit-ready facility designs, Schedule M-III compliance, and process engineering.
Our expert team works closely with medical device manufacturers, startups, and global investors to simplify regulatory compliance, reduce submission timelines, and ensure successful commercialization in India and international markets.
Also Read: CDSCO Notification for Class A Medical Devices: 2026 Guide
Fast-track your CDSCO compliance and MedTech R&D with our experts today.
Publisher | Medical Device Regulatory News and Industry Insights
The Operon Strategist Editorial Team publishes news, updates, and insights on medical device regulations, regulatory policy changes, and global healthcare industry developments. The team covers key regulatory frameworks, including CDSCO, US FDA, EU MDR, ISO 13485, and international market access requirements, helping medical device manufacturers and healthcare businesses stay informed about evolving regulatory expectations.
